MainStreet Investment Advisors LLC acquired a new position in Thermo Fisher Scientific Inc. (NYSE:TMO) in the first quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor acquired 2,384 shares of the medical research company’s stock, valued at approximately $676,000.
Other institutional investors and hedge funds have also recently bought and sold shares of the company. Laurel Wealth Advisors LLC raised its holdings in Thermo Fisher Scientific by 104.3% in the first quarter. Laurel Wealth Advisors LLC now owns 94 shares of the medical research company’s stock worth $27,000 after purchasing an additional 48 shares in the last quarter. Stonebridge Financial Planning Group LLC bought a new position in Thermo Fisher Scientific in the fourth quarter worth $32,000. Ballast Advisors LLC bought a new position in Thermo Fisher Scientific in the first quarter worth $35,000. Savior LLC bought a new position in Thermo Fisher Scientific in the fourth quarter worth $44,000. Finally, Virtus ETF Advisers LLC bought a new position in Thermo Fisher Scientific in the fourth quarter worth $44,000. Institutional investors and hedge funds own 88.68% of the company’s stock.
Several equities analysts have recently weighed in on the company. Wells Fargo & Co raised their price target on Thermo Fisher Scientific from $300.00 to $340.00 and gave the company an “equal weight” rating in a report on Tuesday, April 21st. Needham & Company LLC raised their price target on Thermo Fisher Scientific from $341.00 to $383.00 in a report on Thursday, April 23rd. Stifel Nicolaus reduced their price target on Thermo Fisher Scientific from $345.00 to $315.00 and set a “buy” rating for the company in a report on Thursday, April 2nd. Robert W. Baird raised their price target on Thermo Fisher Scientific from $340.00 to $341.00 and gave the company an “outperform” rating in a report on Wednesday, March 4th. Finally, Citigroup raised their price target on Thermo Fisher Scientific from $365.00 to $390.00 and gave the company a “buy” rating in a report on Thursday, April 23rd. Four research analysts have rated the stock with a hold rating and thirteen have given a buy rating to the company’s stock. The stock has a consensus rating of “Buy” and an average price target of $347.21.
Thermo Fisher Scientific (NYSE:TMO) last released its quarterly earnings data on Wednesday, April 22nd. The medical research company reported $2.94 EPS for the quarter, topping the consensus estimate of $2.79 by $0.15. Thermo Fisher Scientific had a return on equity of 17.25% and a net margin of 14.31%. The company had revenue of $6.23 billion during the quarter, compared to the consensus estimate of $6.18 billion. During the same period last year, the company earned $2.81 EPS. Thermo Fisher Scientific’s revenue for the quarter was up 1.7% on a year-over-year basis. As a group, research analysts predict that Thermo Fisher Scientific Inc. will post 11.92 earnings per share for the current fiscal year.
The company also recently announced a quarterly dividend, which will be paid on Wednesday, July 15th. Shareholders of record on Monday, June 15th will be given a $0.22 dividend. The ex-dividend date of this dividend is Friday, June 12th. This represents a $0.88 annualized dividend and a yield of 0.26%. Thermo Fisher Scientific’s payout ratio is 7.13%.
In other Thermo Fisher Scientific news, CEO Marc N. Casper sold 30,000 shares of the firm’s stock in a transaction dated Tuesday, April 28th. The stock was sold at an average price of $333.02, for a total value of $9,990,600.00. Following the transaction, the chief executive officer now directly owns 304,946 shares of the company’s stock, valued at $101,553,116.92. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, COO Mark Stevenson sold 25,000 shares of the firm’s stock in a transaction dated Friday, April 24th. The stock was sold at an average price of $328.03, for a total value of $8,200,750.00. Following the completion of the transaction, the chief operating officer now directly owns 73,538 shares in the company, valued at $24,122,670.14. The disclosure for this sale can be found here. Company insiders own 0.45% of the company’s stock.
Thermo Fisher Scientific Profile
Thermo Fisher Scientific Inc provides analytical and other instruments, laboratory equipment, software, consumables, reagents, instrument systems, chemicals, supplies, and services under the Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, and Unity Lab Services brands worldwide.
Read More: S&P/ASX 200 Index
Want to see what other hedge funds are holding TMO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Thermo Fisher Scientific Inc. (NYSE:TMO).
Receive News & Ratings for Thermo Fisher Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific and related companies with MarketBeat.com's FREE daily email newsletter.